Health & Fitness
Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009Wed, January 28, 2009Tue, January 27, 2009Mon, January 26, 2009Sun, January 25, 2009Fri, January 23, 2009Thu, January 22, 2009Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2009
//health-fitness.news-articles.net/content/2009/ .. -at-annual-bio-ceo-investor-conference-2009.html
Published in Health and Fitness on Friday, January 30th 2009 at 5:19 GMT, Last Modified on 2009-01-30 05:19:57 by Market Wire🞛 This publication is a summary or evaluation of another publication
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will present a corporate overview at the 11th Annual BIO CEO & Investor Conference on Monday, February 9 at 10:30 a.m. (ET) at the Waldorf=Astoria hotel in New York City.
The presentation will be available via live audio webcast on the Company's website at [ www.iderapharma.com ]. Archived replays will also be located on the Company's site following the event.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit [ www.iderapharma.com ].
Idera Forward Looking Statements
This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on the Company's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's cash resources will be sufficient to fund the its operations; and such other important factors as are set forth under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed on November 6, 2008, which important factors are incorporated herein by reference. The Company disclaims any intention or obligation to update any forward-looking statements.
